GLP1R and Alzheimer disease: Other compounds, such as the natural product cryptotanshinone [95] or the glucagon-like peptide-1 receptor (GLP-1R) agonist Exendin-4 [96], have been tested in Caenorhabditis elegans models of AD, concluding that those drugs can decrease oxidative stress and protein aggregation and improve the disease phenotype.